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Nothing in life is to be feared, it is only to be understood. Now is the time to understand 
more, so that we may fear less. ― Marie Curie
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Abstract  
Cancer diseases are associated with the presence of a wide range of protein biomarkers. 
Aptasensor arrays may enable early multiple-detection of these biomarkers which can make 
important improvements in the lives of cancer patients. Clinical researches suggest that 
osteopontin, an overexpressed protein by tumor cells may be used as a diagnostic biomarker 
for several types of cancer. In this perspective, the objective of this dissertation was to evaluate 
the performance of a previously selected aptamer (C10K7) to detect osteopontin using cyclic 
voltammetry. The electrochemical detection of osteopontin was assessed using different screen-
printed gold electrodes with the selected aptamer immobilized, being determined the detection 
and quantification limits. The specificity of the DNA aptasensor to other proteins was also 
studied using thrombin, lysozyme and bovine serum albumin which were evaluated by a 
previous research as possible interferents. The preliminary work carried out showed that this 
new aptamer allowed achieving a detection limit of 1.3 nM and a quantification limit of 4.0 nM 
for osteopontin. Considering that the reported range of plasma osteopontin concentrations in 
patients with either metastatic or recurrent breast cancer is up to 290 ng/mL (~ 4.46 nM) which 
is higher than the detection and quantification limits found and which suggest that the proposed 
aptasensor could be applied in both osteopontin detection and quantification. On the other hand, 
with the studied aptamer, the detection and quantification limits were lower than those reported 
in the literature for cyclic voltammetry, which were of 2.6 nM for a DNA aptamer (designated 
as C10K2) and 3.7 nM for an RNA aptamer (called OPN-R3). The repeatability assays showed 
a coefficient of variation equal to 7% which demonstrate the closeness of the agreement 
between the results. The evaluation of the specificity of the DNA aptasensor towards 
osteopontin showed little or almost no interference to other proteins. However, the interference 
study showed that the C10K7 aptamer was more prone to interferences from lysozyme and 
bovine serum albumin than the C10K2 aptamer, previously studied by the research team but 
showed a lower interference from thrombin. These results highlight the promising capability of 
the new DNA aptamer (C10K7) to be used in the development of an electrochemical aptasensor 
for the osteopontin detection, which could be foreseen as a diagnosis and therapy monitoring 
tool. Nevertheless, these preliminary satisfactory results need to be further checked, namely by 
the evaluation of its performance for the detection of human osteopontin in biological fluids 
like blood or plasma. 
  Assessing the enhancement performance of a novel aptasensor for osteopontin detection 
YASMINE RIM CHALLOUF  
 
Resumo 
O cancro é uma doença à qual se pode associar a presença de diversas proteínas nos fluidos 
biológicos de pacientes com essa patologia, as quais podem ser usadas como biomarcadores. 
Aptasensores baseados em diferentes aptâmeros selecionados para biomarcadores específicos 
podem permitir a sua deteção num estágio precoce da doença, contribuindo para melhorar a 
vida dos pacientes com cancro. Estudos clínicos sugerem que a osteopontina, é uma proteína 
sobre-expressa por células tumorais, podendo ser utilizada como biomarcador no diagnóstico 
de vários tipos de cancro. O objetivo do presente trabalho foi avaliar o desempenho de um 
aptâmero previamente selecionado (C10K7) para detectar osteopontina recorrendo à técnica de 
voltametria cíclica. O estudo realizado permitiu verificar que este novo aptasensor possui um 
limite de deteção de 1.3 nM e um limite de quantificação de 4.0 nM. Estes valores permitem 
antever a aplicabilidade prática deste dispositivo como uma ferramenta de deteção de 
osteopontina uma vez que as concentrações reportadas em plasma de pacientes com o cancro 
são da ordem dos 4.46 nM (290 ng/mL). Por outro lado, convém referir que o novo aptasensor 
apresenta limites de detecção e de quantificação inferiores aos descritos na literatura para outros 
aptasensores baseados em aptâmeros de RNA (OPN-R3) e DNA (C10K2), nomeadamente 3.7 
nM e 2.6 nM, também estabelecidos por voltametria cíclica. Os ensaios de repetibilidade 
realizados mostraram que o aptasensor desenvolvido apresentava um desempenho satisfatório 
(coeficientes de variação inferiores a 7%). Por fim, o novo aptasensor mostrou-se bastante 
específico relativamente à osteopontina, molécula alvo, com reduzida interferência por parte de 
outras protéinas tipo (lisozima, albumina bovina e trombina). Os resultados obtidos sãp bastante 
promissores indicando o novo aptasensor de DNA (C10K7) uma possível ferramenta de 
diagnóstico e/ou monitorização da evolução do cancro. No entanto, o desempenho satisfatório 
descrito terá de ser validado na deteção de osteopontina humano em líquidos biológicos como 
o sangue ou o plasma. 
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1. Introduction  
1.1. Cancer 
The general term "cancer" refers to a broad group of diseases that can affect any part of the 
body (Bhatt et al., 2010). The apparition of cancer is due to the transformation of normal cells 
into tumour cells, a process that goes through many stages, with a classic progression to a 
precancerous lesion and after that to a malignant tumour (Bhatt et al., 2010). These 
modifications come from interactions between external agents and the genetic factors specific 
to the subject (Bhatt et al., 2010). 18.1 million new cases and 9.6 million cancer deaths were 
estimated to occur worldwide in 2018 (Bray et al., 2018). Table 1 presents the new cases and 
deaths for the top 10 cancers in 2018. It is estimated that nearly one‐half of the cases and over 
one‐half of the cancer deaths in the world will occur in Asia in the year 2018, especially because 
close to 60% of the global population resides there (Bray et al., 2018). Europe accounts for 
23.4% of the total cancer cases worldwide and 20.3% of the cancer deaths, even though it 
represents only 9% of the global population, followed by the Americas’ 21% of incidence and 
14.4% of mortality worldwide (Bray et al., 2018). 
For both sexes combined, lung cancer is the most commonly diagnosed cancer with 11.6% of 
the total cases and the leading cause of cancer death with 18.4% of the total cancer deaths, then 
followed closely by female breast cancer with 11.6%, colorectal cancer with 10.2%, and 
prostate cancer with 7.1% (Bray et al., 2018). By sexes, lung cancer is the most frequently 
diagnosed cancer and the leading cause of cancer death in males, followed by colorectal and 
prostate cancer for incidence, and stomach and liver cancer for mortality. Among females, 
breast cancer is considered the most commonly diagnosed cancer and the leading cause of 
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Table 1. New cases and deaths for the top 10 cancers in 2018. 
 
Cancer site  Number of new cases Number of deaths 
Lung 2,093,876 1,761,007 
Breast 2,088,849 626,679 
Prostate 1,276,106 358,989 
Colon  1,096,601 551,269 
Nonmelanoma of skin 1,042,056 65,155 
Stomach 1,033,701 782,685 
Liver 841,080 781,631 
Rectum 704,376 310,394 
Esophagus 572,034 508,585 
Cervix uteri 569,847 311,365 
 
One of the hallmarks of cancer is the rapid proliferation of abnormal cells that, beyond their 
usual boundaries, can invade adjacent parts of the body and then spread to other organs. This is 
known as metastasis, which is the leading cause of death from cancer. This proliferative 
potential and survival advantage of cancer cells are caused by alterations in the status and 
expression of primarily three main classes of genes: 
Proto-oncogenes: Proto-oncogenes are a group of genes that lead normal cells to become 
cancerous when they are mutated (Adamson et al.,1987; Weinstein et al., 2006). 
Mutations in proto-oncogenes are in general dominant in nature, and we call the mutated 
version of a proto-oncogene an oncogene. Frequently, proto-oncogenes encode proteins that 
function to stimulate cell division, inhibit cell differentiation, and halt cell death. All of these 
processes are important for normal human development and for the maintenance of organs and 
tissues. Oncogenes, nonetheless, typically exhibit increased production of these proteins, 
therefore leading to increased cell division, decreased cell differentiation, and inhibition of cell 
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death, if we take them together, we can say that these phenotypes define cancer cells. Thus, 
oncogenes are currently a major molecular target for anti-cancer drug design (Weinstein et al., 
2006). 
Tumour suppressor genes: A tumour suppressor gene, or antioncogene, is a gene that protects 
a cell from one step on the path to cancer (Weinberg et al., 2014). When this gene mutates to 
cause a loss or reduction in its function, the cell can progress to cancer, usually in combination 
with other genetic changes. The loss of these genes may be even more important than proto-
oncogene/oncogene activation for the formation of many kinds of human cancer cells. tumour 
suppressor genes can be grouped into categories including caretaker genes, gatekeeper genes, 
and landscaper genes, the classification schemes are evolving as medicine advances, learning 
from fields including molecular biology, genetics, and epigenetics (Weinberg et al., 2014). 
DNA repair genes: DNA repair is a collection of processes by which a cell identifies and 
corrects damage to the DNA molecules that encode its genome (Wood et al., 2001). In human 
cells, both abnormal metabolic activities and environmental factors such as radiation can cause 
DNA damage, resulting in as many as 1 million individual molecular lesions per cell per day. 
Many of these lesions cause structural damage to the DNA molecule and can alter or eliminate 
the cell's ability to transcribe the gene that the affected DNA encodes. Other lesions induce 
potentially harmful mutations in the cell's genome, which affect the survival of its daughter 
cells after it undergoes mitosis. As a consequence, the DNA repair process is constantly active 
as it responds to damage in the DNA structure. When normal repair processes fail, and when 
cellular apoptosis does not occur, irreparable DNA damage may occur, including double-strand 
breaks and DNA cross-linkages (interstrand crosslinks or ICLs). This can eventually lead to 
malignant tumours or cancer. The accumulation of errors can overwhelm the cell and result in 
cancer (Wood et al., 2001) and when faulty genes are inherited from parents, the risk of cancer 
is higher (Harris, 2015). On the other hand, the detection of advanced cancer and the inability 
to access diagnosis and treatment are common problems. 
Finally, treatment is more likely to be effective, with a better chance of survival, reduced 
morbidity and lower the costs if the cancer is diagnosed in an early stage. Early diagnosis is 
useful in all situations for the majority of cancers. When the diagnosis is made at an advanced 
stage, curative treatment is sometimes no longer possible, that’s why researchers are trying to 
develop new tools and methods that can help detect cancer in an early stage, in this context it 
is possible to talk about biomarkers, which are attracting more and more scientists who suggest 
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that it is possible to detect cancer at an early stage thanks to their specificity (Meirinho et al., 
2015). 
1.2. Cancer biomarkers  
Cancer biomarkers are the substances produced by normal cells as well as cancer cells in 
response to cancer that can be found in the blood, tumour tissue, urine or other body fluids 
(Gam., 2012). National Institutes of Health Biomarkers Definitions Working Group defined a 
biomarker as “a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”. 
Biomarkers can be used for patient assessment in many clinical settings, including estimating 
risk of disease, screening for occult primary cancers, determining prognosis and predict ion for 
patients diagnosed with cancer, distinguishing benign from malignant findings or one type of 
malignancy from another, and monitoring status of the disease, either to detect recurrence or 
determine progression or response to therapy (Henry et al., 2012). 
For example, the Pro2PSA1 which is a biomarker for prostate cancer, it is used in discriminating 
cancer from benign disease. Also, the OVA1 (multiple proteins) which is a biomarker for 
ovarian cancer, it’s used in the prediction of malignancy, we have as well the CA27.29, a 
biomarker of breast cancer, its clinical use is monitoring disease response to therapy (Wei et 
al., 2016). 
There are three main categories of cancer biomarkers, namely diagnostic, prognostic and 
predictive biomarkers (Goossens et al., 2015). A diagnostic biomarker is used to detect the 
presence of the disease and is present in any stage during cancer development (Mishra et al., 
2010). Bladder tumour antigen (BTA) and nuclear matrix protein-22 (NMP-22) are examples 
of approved diagnostic biomarkers by the Food and Drug Administration (FDA) for bladder 
cancers (Lau et al., 2009). A prognostic biomarker is used to predict the course of the disease 
and to indicate the aggressiveness of the tumour (Gam, 2012). As an example, the glycoprotein 
CA125 is a prognostic biomarker of ovarian cancer (Huang et al., 2010). A predictive marker 
is used to predict the response of a patient to particular therapeutic interventions. For instance, 
the predictive biomarker human epidermal growth factor receptor HER2 can tell us about the 
response to trastuzumab in breast cancer (Henry et al., 2012).  
On the basis of biochemical molecules, cancer biomarkers have a broad range of entities, like 
RNA, DNA, micro RNA, proteins, lipids, carbohydrate and small metabolites, cytokinetic and 
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cytogenetic parameters found in the body fluid (Bhatt et al., 2010). Proteomic markers are the 
most important biomarkers since they are the main executioner molecules in cells, they are also 
more relevant to the disease state initiation and progression (Srivastava et al., 2005). 
Unfortunately, most of the available biomarkers lack the specificity and sensitivity to be used 
in early detection (Gam, 2012). For example, CA27.29, CA15.3, and CEA are breast cancer 
biomarkers approved by the FDA but they are useful only for monitoring advanced breast 
cancers (Mirza et al., 2008). 
1.2.1. Examples of cancer biomarkers 
ROMA (HE4+CA-125): Ovarian Cancer biomarkers: 
Ovarian cancer is one of the three most common malignant tumours in the female reproductive 
system. It has an insidious onset with a difficult early diagnosis (Wei et al., 2016). In 
approximately 70% of all cases of ovarian cancer, the disease is not diagnosed before reaching 
an advanced stage (Zhang et al., 2004). The 5-year survival rate associated with ovarian cancer 
is lower than 30% (Heintz et al., 2006). Over 90% of all cases of ovarian masses detected in 
premenopausal and 60% in postmenopausal women are benign (Enakpene et al., 2009). The 
early diagnosis of ovarian malignant tumour becomes a key factor in improving the survival 
rate of patients. Tools currently in use for differentiating between low- and high-risk patients 
with ovarian cancer are the tumour markers carbohydrate antigen-125 (CA-125) and the human 
epididymis protein 4 (HE4), as well as the value of the risk of ovarian malignancy algorithm 
(ROMA) (Karlsen et al., 2012). Table 2 presents the diagnostic values of CA-125, HE4 and 
ROMA in ovarian cancer compared with the standard. 
 
Table 2. The diagnostic values of CA-125, HE4 and ROMA in ovarian cancer and benign 
tumour compared with the healthy control (Wei et al., 2016). 
 






Cases 30 64 64 
HE4 (pmol/l) 39.04 ±8.38 54.76 ±42.35 739.04 ±860.04 
CA-125 (U/ml)  15.08 ±5.28 49.07 ±175.61 868.85 ±1204.08 
ROMA index 6.18 ±2.21 10.15 ±11.98 76.30 ±28.57 
ROMA index = 8.09 + 1.04 × ln (HE4) + 0.732 × ln (CA-125) 
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CEA, NSE, TPS: Lung cancer biomarkers: 
Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in 
cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, 
but the production stops before birth. Consequently, CEA is usually present at very low levels 
in the blood of healthy adults (about 20 ng/mL). However, the serum levels are raised in some 
types of cancer, which means that it can be used as a tumour marker in clinical tests. Serum 
levels can also be elevated in heavy smokers (Asadet al., 2016). 
Neuron-specific enolase (NSE) is an important indicator for monitoring tumour progression 
in the lung cancer patient. Previous studies suggested that the higher the NSE, the worse 
prognosis of NSCLC patients (Stosic, 2006). 
Tissue polypeptide specific antigen (TPS) is valuable to diagnosis, response monitoring for 
patients with lung cancer, moreover, it may be a useful factor of prognosis of non-small cell 
lung cancer (Wang et al., 2010). Additionaly, some biomarkers are more specific to a certain 
type of cancers than others. Table 3 presents the comparative levels of CEA, NSE and TPS in 
the blood plasma of patients with adenocarcinoma and squamous lung cancer and healthy 
people.  
 
Table 3. Comparative levels of well-known lung cancer biomarkers (CEA, NSE, TPS) in the 









CEA 30.76 ng/mL 4.49 ng/mL <5.0 ng/mL 
NSE 17.95 ng/mL 16.83 ng/mL 15.7–17.1 ng/mL 
TPS 10–3842 ng/mL 0–3000 ng/mL 34.9 ng/mL 
 
A list of FDA-approved protein tumour markers used in clinical practice and mentioned 
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Table 4. List of FDA-approved protein tumour markers currently used in clinical practice 
(adapted from Ry et al., 2013).  
 
Biomarker Clinical use Cancer type Specimen 
Pro2PSA Discriminating cancer from 
benign disease 
Prostate Serum  
ROMA (HE4+CA-125) Prediction of malignancy Ovarian Serum 
OVA1 (multiple proteins) Prediction of malignancy Ovarian Serum 
HE42 Monitoring recurrence or 





Monitoring progression of the 
disease 
Colorectal Serum 
AFP-L3% Risk assessment for the 
development of disease 
Hepatocellular  Serum  
p63 protein Aid in differential diagnosis Prostate FFPE tissue 
Circulating tumour Cells 
(EpCAM, CD45, 
cytokeratins 8, 18+, 19+) 
Prediction of cancer 
progression and survival 
Breast  Whole blood 
c-Kit Detection of tumours, aid in 




CA319-9 Monitoring disease status Pancreatic Serum, 
Plasma 
Estrogen receptor (ER) Prognosis, response to therapy Breast FFPE tissue 
Progesterone receptor 
(PR) 
Prognosis, response to therapy Breast FFPE tissue 
HER-2/neu Assessment for therapy Breast FFPE tissue 
CA-125 Monitoring disease 
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Table 4. (continued).  
 
CA27.29 Monitoring disease response to 
therapy 
Breast Serum 
Free PSA4 Discriminating cancer from 
benign disease 
Prostate Serum 
Thyroglobulin Aid in monitoring Thyroid Serum, 
plasma  
Note: Pro2PSA (pro-prostate specific antigen); HE4 (Human epidymis protein); CA19-9 (caner 
antigen); PSA (Prostate-specific antigen). 
 
Actually, several works reported osteopontin as an important candidate biomarker for human 
cancer (Psyrri et al., 2017; Hao et al., 2016; Ferreira et al., 2016; Nassar et al., 2015; Weber., 
2011; Ahmed et al. 2011). But it has not yet been used in clinical diagnostics. 
 
1.3. Osteopontin 
1.3.1. Definition of osteopontin 
Osteopontin (OPN) is a negatively charged aspartic acid-rich, N-linked glycosylated 
phosphoprotein and it is composed of 314 amino acid residues (Kadkol et al., 2006; Scatena et 
al., 2006). Figure 1 presents the tertiary structure of the osteopontin. The localization of the 
human gene for osteopontin is in the long arm of chromosome 4q13 directly related to four 
similar genes encoding for bone sialoprotein (BSP), dentin sialophosphoprotein (DSPP), dentin 
matrix protein 1 (DMP1), and matrix extracellular phosphoglycoprotein (MEPE) (Fedarko et 
al., 2004). Due to common functional motifs and domains, these five integrin-binding 
glycophosphoproteins are categorized as the so-called SIBLING proteins (small integrin-
binding ligand N-linked glycoproteins) (Bellahcene et al., 2008). Osteopontin is encoded by a 
single copy gene, but as a result of alternative splicing, alternative translation and different post-
translational modifications (PTMs), it exists in various isoforms, which allow for a molecular 
weight ranging from 41 to 75 kDa (Anborgh et al., 2011). OPN has primarily been described 
as a secreted protein involved in several physiological as well as pathological events. However, 
current evidence suggests that OPN can also be found in the cytoplasm and the nucleus (Junaid 
et al., 2007). This form of intracellular OPN (iOPN) is the result of alternative translation and 
has biological functions distinct from those of secreted OPN (sOPN) (Inoue et al., 2011).  
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OPN contains an integrin-binding RGD sequence which interacts with CD44v 6/7, that is a cell 
surface glycoprotein involved in cell-cell interactions. OPN can also activate intracellular 




Clinical studies have revealed that higher expression of osteopontin is found in tumour tissue 
and serum of different types of cancers suggesting that osteopontin may be used as a diagnostic 
and prognostic biomarker for various cancers (Weber et al., 2010). Actually, altered osteopontin 
levels have been associated with breast cancer (Psyrri et al., 2017; Macrì et al., 2009), thyroid 
cancer (Ferreira et al. 2016), leukemia (Liersch et al., 2015), colorectal cancer (Huang et al., 
2016), lung cancer (Shojaei et al., 2012), ovarian cancer (Huang et al., 2010), gastrointestinal 
stromal tumours (Hsu et al., 2010), pancreatic (Collins et al., 2012) and renal cell carcinoma 
(Matušan-Ilijaš et al., 2011). Osteopontin acts like an important molecule that is involved in all 
the stages of cancer progression including tumour invasion, angiogenesis and metastasis 
(Ahmed et al., 2011). There is well-documented evidence to suggest that osteopontin 
contributes to tumour progression (Zhao et al., 2018). It acts as an important and overexpressed 
molecule at different steps of the cancer process. Added to that, OPN has demonstrated a role 
in the development of various solid organ tumours via different mechanisms. As presented in 
figure 2 by Zhao et al. (2018), in breast, brain, prostate and ovarian cancers, OPN has been 
shown to preferentially bind to a variety of integrins including αvβ1, αvβ5, αvβe and αvβ3, that 
result in an increase in cell adhesion, migration, and invasion, whilst OPN has been shown to 
Figure 1. Tertiary structure of the osteopontin (Sivakumar et al., 2014). 
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bind to both integrin and CD44 receptors in lung cancers (Zhao et al., 2018). In addition to 
receptor binding, OPN is involved in enhancing MMP release and as a result increasing cell 
invasiveness and tumour growth in brain, liver, ovarian, colorectal, pancreas and prostate, and 
oesophageal and gastric cancers. OPN-mediated upregulation of the PI3K/Akt signaling 
pathway is a common feature of liver, lung, ovarian and prostate tumour progression, thus 
preferentially regulating cell survival, cell cycle progression and cellular growth in favor of 
tumour development (Zhao et al., 2018). The activation of VEGF and its downstream effector, 
HIF-1α, by OPN may occur dependently or independently of PI3K/Akt activation and promotes 
tumour angiogenesis, recruitment of endothelial cells and tumour growth, particularly in the 
colorectal, pancreatic, lung, and esophageal and gastric malignancies. Activation of the JNK 
pathway by OPN has been shown to be most specific to colorectal cancer, whilst the precise 
role of OPN in bladder and kidney cancers, particularly, remains to be elucidated.  
Eventually, it has been demonstrated that high levels of OPN favor the survival and 
proliferation of cancer cells at the primary site (Zhao et al., 2018). 
However, further research is necessary to improve the current understanding of these various 
molecular pathways and elucidate the precise role of OPN in mediating cancer progression and 
metastasis. Finally, OPN has the potential to be a novel biomarker and anti-cancer therapeutic 
target (Zhao et al., 2018) that’s why it is important to focus on OPN detection methods. 
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Figure 2. The role of osteopontin in various solid organ tumours (Zhao et al., 2018). 
 
1.3.2. Osteopontin detection 
The enzyme-linked immunosorbent assay (ELISA) method currently dominates the field of 
protein quantification and detection (Li et al., 2016). Bramwell et al. (2014) used an ELISA 
technique to measure the osteopontin levels in plasma samples of patients with breast cancer. 
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In general, ELISA is a biochemical test that uses antibodies and an enzyme-mediated color 
change to detect the presence of an antigen like proteins, hormones, peptides or antibody in a 
given sample (Gan et al., 2013). Although its widespread use, there are some limitations that 
have to be considered. In fact, nonspecific binding of the antibody or antigen to the plate will 
lead to a falsely high-positive result. In addition to that ELISA cannot distinguish between 
antigenically identical analytes. For now, the same ELISA assay will often recognize many or 
all different isoforms of the same protein in a sample. Additionally, the assay requires some 
specialized equipment, like a spectrophotometric microplate reader, large amounts of sample 
and skilled technicians (Chatziharalambous et al., 2016; Li et al., 2016). Therefore, it is urgent 
to develop new detection techniques for protein cancer biomarkers that circumvent the above-
mentioned limitations of conventional ELISA. In that case, the biosensor is considered a 
promising alternative for osteopontin detection.  
 
1.4. Biosensors 
According to the International Union of Pure and Applied Chemistry (IUPAC) “a biosensor is 
a self-contained integrated device which is capable of providing specific quantitative or semi-
quantitative analytical information using a biological recognition element (biochemical 
receptor) which is in direct spatial contact with a transducer element” (Labuda et al., 2010; 
Thévenot et al., 2001). Another commonly used definition for biosensors is “analytical devices 
that are based on a bioreceptor and that are capable of sensing biologically-relevant analytes 
with either electrical or optical readout” (Cheng et al., 2009). 
They are powerful analytical devices that consist of a bioreceptor compound such as an 
antibody or nucleic acid immobilized on a transducer surface, which is capable of providing a 
signal due to the interaction between the bioreceptor and the analyte (Vigneshvar et al., 2016). 
Figure 3 presents the schematic illustration of a biosensor. Biosensors are able to detect a wide 
range of analytes in complex matrices and have been applied in many fields such as food 
industry, medical field and environmental monitoring. They provide better stability and 
sensitivity as compared with conventional methods such as enzyme-linked immunosorbent 
assays, 2-D western blotting and 2-D gel electrophoresis (Kraatz et al., 2015; Mehrotra, 2016). 
The main components of biosensors are: 
- The bioreceptors (biorecognition elements) which could specifically recognize and 
identify the target (Han et al., 2010).  
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- Signal transducer, which could transform the biological signal into an electrical signal 
with high sensitivity and minimum disturbance to the measured analyte.  
- A display which transforms the measured electrical/optical signal into a digital format 
for end-users (Cheng et al., 2009; Han et al., 2010). 
The existing biosensors can be classified into immunosensors, enzymosensors, aptasensors, etc. 
based on the nature of the bioreceptor such as antibodies, enzymes and aptamers, respectively 
(Mehrotra., 2016). The principal components of all biosensors are transducers or the detector 
devices, displays or electronic parts comprised by a signal amplifier and the data processor, and 
the bioreceptors or biorecognition elements (Cheng et al., 2009; Strehlitz et al., 2008; Velusamy 
et al., 2010). 
 
Figure 3. Schematic illustration of a biosensor (Meirinho, S.G., 2016).  
 
The general purpose of a biosensor is to produce either discrete or continuous signals that are 
proportional to a property of a single target or a related group of analytes. After that, the signals 
are transformed into a digital format that can be recognized by the end users (Strehlitz et al., 
2008). The interaction between the bioreceptor and the target is the result in one or more 
physicochemical modifications like electron transfer, pH modifications, mass variation, heat 
transfer and gases or ions release that the transducer can detect and measure them (Kumar et 
al., 2012). The bioreceptor will be responsible for the specific sensor response to a given target 
or group of targets of interest, therefore minimizing the interference from other substances in 
complex mixtures (Viswanathan et al., 2008). The choice of the bioreceptor is very important 
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in the development of a biosensor because it determines its selectivity and specificity. On the 
other hand, the transducer determines the sensitivity of the biosensor and is responsible for 
converting the biological signal into a measurable signal (Monošík et al., 2012; Sassolas et al., 
2009). Usually, biosensors can be classified according to the bioreceptors type and signal 
transduction or transducer. Bioreceptors are generally grouped in five classes, namely enzymes, 
antibodies/antigens, nucleic acids, cellular structures/cells and recently biomimetic materials or 
synthetic bioreceptors (e.g. aptamers) (Velusamy et al., 2010). Added to that, according to the 
method used for the signal transduction, the biosensor can be grouped in different classes, such 
as electrochemical, optical and mass sensitive (Grieshaber et al., 2008). Biosensors are an 
attractive analytical tool in several areas due to the selectivity and sensitivity of the bioreceptor 
and the transducer and they are applicable to a large variety of samples including body fluids, 
food, cell cultures and environmental samples (Cheng et al., 2009; Grieshaber et al., 2008; 
Sassolas et al., 2009). The specific application of a biosensor determines the best 
electrochemical technique to use, as long as each detection method presents advantages and 
disadvantages. The electrochemical transduction presents considerable advantages over optical, 
piezoelectric or thermal detection (Deng et al., 2013; Radi, 2011), such as high sensitivity and 
selectivity, the ability to work with turbid samples, inherent miniaturization, compatibility with 
novel microfabrication technologies, disposability and accuracy, simplicity, robustness, 
possibility of usage for on-line control, fast response, and relatively low manufacturing cost, all 
of these advantages are making electrochemical aptasensors very attractive for diagnostic and 
use in point-of-care devices, also for simultaneous multi-analyte detection (Arshak et al., 2009; 
Radi, 2011; Saberian et al., 2011; Song et al., 2008; Velasco-Garcia and Missailidis, 2009; 
Velusamy et al., 2010; Xu et al., 2009).  
 
1.5. Aptasensor: a class of biosensor 
An aptasensor is a particular class of biosensor where the biological recognition element is a 
DNA or an RNA aptamer. In an aptasensor, the aptamer recognizes the molecular target towards 
which it was previously selected in vitro (Duan et al., 2016). Compared to other existing 
biological recognition elements, aptamers exhibit several advantages in terms of stability, 
design flexibility, and cost-effectiveness. To name a few, stability to long-term storage and 
under a wide range of buffer conditions, easy synthesis, resistance to denaturation and 
degradation, reversible thermal denaturation and ability to bind to targets with selectivity, 
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specificity, and affinity, equal and often superior to those of monoclonal antibodies (Lowe 
2008; Meirinho et al., 2015; Moreno, 2014).  
1.5.1. Electrochemical aptasensors  
In electrochemical aptasensors an electrode surface is used to immobilize the aptamer and an 
electrochemical transducer is held for monitoring the aptamer-target interaction, by detecting 
current or potential changes that take place at the transducer/bioreceptor interface/surface 
(Hong et al., 2012; Monošík et al., 2012; Sadik et al., 2009; Thévenot et al., 2001).  
Different voltammetry techniques can be used among voltammetric biosensors such as cyclic 
voltammetry (CV), differential pulse voltammetry (DPV), square-wave voltammetry (SWV) 
and alternating current voltammetry (ACV). The application of a potential to a working 
electrode versus a reference electrode is the characterization of the voltammetric biosensors. 
The corresponding current is a result of electrolysis by means of an electrochemical reduction 
or oxidation at the working electrode. In the voltammetric biosensors, the potential is scanned 
over a set potential range and both the current and potential are recorded and measured. In case 
it’s an amperometric or voltammetric biosensor, the recorded current response is proportional 
to the concentration of the target molecule in the sample (Grieshaber et al., 2008; Kumar et al., 
2012; Liu., 2000; Rahman et al., 2008; Ronkainen et al., 2010; Viswanathan et al., 2008). 
Among the voltammetric aptasensors, those based on CV, DPV and SWV are the most 
frequently used. However, to evaluate the electrode surface, namely its reproducibility, 
stability, purity and repeatability, the CV technique can be used. It may also be used for cleaning 
and for monitoring the immobilization of aptamers on the electrode surface since it allows a 
fast visualization of the redox behavior over a wide potential range (Ferreira et al., 2011). Added 
to that, CV technique can also be used to study the performance of an electrochemical 
aptasensor during the detection of several molecules, such as proteins (Cheng et al., 2007; 
Meirinho et al., 2015; Wang et al., 2009; Yuan et al., 2011). 
An exceptional advantage of voltammetric biosensors is the low related noise observed, hence 
providing reliable and reproducible data for the quantification of a target molecule, which can 
endow the biosensor with higher specificity and sensitivity (Labib et al., 2014). 
Areas, where electrochemical aptasensors can be applied, are very diversified such as health 
like in clinical diagnostic and for therapeutic purposes, food industry and environmental 
monitoring for the detection of protein disease biomarkers, pathogens and small molecules, 
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respectively (Hayat et al., 2014; Hong et al., 2012; Kim et al., 2014; Labib et al., 2014; Liu et 
al., 2012; Palchetti et al., 2012). 
Aptasensors has also been used in recent researches to detect other cancer biomarkers such as 
the development of an electrochemical sensor using the 76-nucleotide DNA ERα- aptamer for 
precise, cost-effective and rapid, detection of estrogen receptor alpha (ERα) expression in 
human breast cancer patients (Ahirwar et al., 2018). Indeed, the analysis of estrogen receptor 
(ERα) expression in breast carcinomas plays an important role in the determination of the 
endocrine responsiveness of tumours for systemic adjuvant therapy. Also, electrochemical 
aptasensors have been used to early detect prostate-specific and free prostate-specific antigens 
released by cancer cells (Parra et al., 2018). It is a simple and non‐invasive methodology to 
detect prostate cancer.  
1.5.2. Aptamers as bioreceptors 
Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule. (≈ 
12-80 nucleotides long) they are formed by single-stranded DNA or RNA, they possess unique 
binding characteristics to their targets, like high sensitivity, high affinity, specificity and ability 
to fold into numerous tertiary conformations (e.g. hairpin, G-quartet, stem-bulge, pseudoknot, 
T-junction) (Cho et al., 2009; de-los-Santos-Álvarez et al., 2008; Famulok and Mayer, 2011; 
Lakhin et al., 2013; Meyer et al., 2011; Radom et al., 2013).  
They are usually created by selecting them from a large random sequence pool. This selection 
methodology is termed SELEX (systematic evolution of ligands by exponential enrichment) 
(Cheng et al., 2009).  
1.5.3. SELEX: Methodology to select aptamers 
The SELEX methodology also referred to as in vitro selection or in vitro evolution, is 
a combinatorial chemistry technique in molecular biology for producing aptamers, it starts with 
a chemically synthesized random oligonucleotides library (up to 1015 different sequences). As 
presented in Figure 4, the selection process can be divided into 3 steps, namely binding, 
separation/partitioning and amplification, which are iteratively repeated to obtain nucleotides 
having improved binding ability towards the desired target. After a number of cycles (generally 
5–15 cycles), the sequences obtained are cloned, sequenced and their binding affinity, 
secondary structure and Gibbs energy are evaluated in order to select the aptamers with high 
specificity and affinity to the target molecule (Darmostuk et al., 2015; Dua et al., 2011; Radom 
et al., 2013; Santosh et al., 2014; Song et al., 2012; Syed et al., 2010; Vikesland et al., 2010). 
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Figure 4. Systematic Evolution of Ligands by Exponential Enrichment (SELEX) 
methodology (Meirinho et al., 2016). 
 
Up to now, a variety of aptamers exhibiting high selectivity and affinity towards relevant 
protein disease biomarkers have been reported, thus allowing the fabrication of new, simple 
and sensitive diagnostic methods to determine such proteins in standard solutions and in 
complex samples such as blood and serum. The use of electrochemical aptasensors is 
particularly interesting given their simplicity, sensitivity, specificity and suitability for the 
detection of low levels of protein disease biomarkers using several available techniques 
including CV, SWV and DPV. 
In this work, we are going to use a DNA aptamer to detect osteopontin for the reason that DNA 
aptamers are suitable for designing reusable aptasensors while RNA aptamers allow single-shot 
measurements since they are more susceptible to nucleases attack (Sassolas et al., 2009; 
Strehlitz et al., 2008). 
 
1.6. Objectives 
The aim of this work is to assess the enhancement performance of a novel DNA aptasensor for 
osteopontin detection, based on a new DNA aptamer, which was previously obtained using 
SELEX methodology. For that, electrochemical tools were used, being aimed to characterize 
the performance of a new aptasensor using cyclic voltammetry. The objectives are to assess the 
electrochemical detection of human osteopontin using different screen-printed gold electrodes 
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and the selected aptamer to determine the detection and quantification limits. The evaluation of 
repeatability assays in order to calculate the coefficient of variation. The study of the specificity 
of the DNA aptasensor to other proteins using thrombin, lysozyme and bovine serum albumin 
which were evaluated by a previous research as possible interferents. 
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2. Material and methods  
2.1. Reagents  
Sodium chloride (NaCl), potassium chloride (KCl) and sodium hydrogen phosphate 
(Na2HPO4) were obtained from Panreac. Potassium hexacyanoferrate (III) [K3Fe(CN)6] and 
potassium hexacyanoferrate (II) [K4Fe(CN)6] were acquired from Acros Organics and 
potassium dihydrogen phosphate (KH2PO4) from Merck. 3,3-dithiodipropionic acid (DPA), 
N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC), N-
hydroxysuccinimide (NHS), ethanolamine (ETA), and streptavidin were purchased from 
Sigma-Aldrich. Recombinant human OPN (rhOPN), was obtained from R&D systems and 
manipulated according to the manufacturers’ specifications. 
2.2. Solutions  
Stock solutions of 100 mM of NHS, 200 mM of EDC, additionally to the stock solution of 1 
mg/ml streptavidin in PBS (pH 7.4) were prepared and stored at -20 ºC before use. Phosphate 
buffer saline (PBS) was prepared to contain 2.7 mM KCl, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 
137 mM NaCl and 2.7 mM KCl, with adjusted pH 7.4. The redox probe was prepared in order 
to obtain a solution with a concentration of 5 mM K4Fe(CN)6: K3Fe(CN)6 (1:1) and with 10 
mM of KCl in 100 mL of PBS, at pH 7.4. Stock solutions of 100 mM of ETA and 200 nM of 
DPA were prepared and stored at 4 ºC. Stock solutions of protein were prepared according to 
manufacturer specifications and stored at -20 ºC. The protein working solutions were prepared 
and diluted to a concentration of 200nM with PBS buffer and stored at 4 ºC before use.  
2.3. Apparatus and software 
The pH was measured using a pH meter (iHANNA instruments pH 211). A DropSens 
potentiostat (µStat 200, reference DRP – STAT200) was used to record CV signal profiles 
(Figure 5). The disposable screen-printed gold electrodes (SPGEs) chip (reference C223AT - 
high temperature curing ink, DropSens, S.L., Spain) used had a gold working electrode with a 
diameter of 1.6 mm, as well as a silver pseudo-reference electrode and a gold counter electrode 
(Figure 6). A DropSens connector (µStat cable connector, reference CAST, DropSens, S.L., 
Spain) was used as an interface between the SPGEs and the DropSens potentiostat (Figure 5). 
The Drop View 2.0 software was used to study the electrochemical processes taking place at 
the electrode’s surfaces. 
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Figure 6. Screen-printed gold electrode (reference C223AT, DropSenses). 
 
2.4. DNA aptamer  
The DNA aptamer (C10K7) against human OPN has been isolated through the SELEX 
methodology as described before. The sequence of the biotinylated DNA aptamer that was 
synthesized by Integrated DNA Technologies (Belgium) is as follows: 5’- Biotin- CAT AAC-
ACG GTA ATT GTG TGA ACC GCT GTG -3’. The stock solutions of the synthetic 
oligonucleotides were prepared with distilled water. The working DNA aptamer solution was 
prepared every day by dilution to the desired concentration (8 nM) using PBS. 
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2.5. Immobilization of the DNA aptamer on a gold surface  
The use of an efficient immobilization method and a specific aptamer are required to construct 
an electrochemical-based aptamer biosensor with high affinity for rhOPN. The biotinylated 
DNA aptamer was immobilized onto the screen-printed gold electrode (SPGE) by a 
streptavidin-biotin interaction. To get to immobilize the aptamer the following steps were made: 
first of all, the electrode was electrochemically cleaned by successively cycling the electrode 
using three sulfuric acid solutions (0.5 M H2SO4, 0.01 M KCl/0.1 M H2SO4 and 0.05 M H2SO4) 
under electric potential in the range of -0.3 to 1.5 V, and with a scan rate of 100 mV/s. The 
cleaning procedure ended when a representative cyclic voltammogram of a clean gold electrode 
was obtained. In order to ensure the uniformity of the working electrode, [Fe(CN)6]
-3/-4 solution 
was used to verify if the typical CV voltammogram of homogenized gold electrode was 
reached. After that, the self-assembled monolayer (SAM) was spontaneously formed through 
incubation of 200 mM of DPA for 30 min. After washing with deionized water, the working 
electrode was treated, during 1 hour, with the same volumes of 1 mM of NHS and 100 mM of 
EDC in order to activate the carboxyl groups, so that they can bind with the amino-terminal of 
streptavidin. After that, the working electrode was incubated overnight with streptavidin 
solution at 4 ºC. After washing with PBS 1×, the working electrode was then exposed to ETA 
(100 mM, pH 8.5) for 20 min in order to block any remaining activated -COOH groups. Finally, 
the DNA aptamer in PBS buffer (pH 7.4) was attached to the modified gold surface using the 
streptavidin-biotin interaction for 40 min. All reactions were carried out at room temperature.  
2.6. Osteopontin incubation  
Standard solutions of rhOPN in PBS buffer (200nM) were dropped on the working electrode 
and incubated for 1 hour. After washing the electrode with PBS 1×, 60μL of [Fe(CN)6]
-3/-4 
solution was dropped on the electrodes chip until all three electrodes were immersed. Then, 
cyclic voltammetry (CV) was performed and an electrochemical signal was generated due to 
the aptamer-target molecule interaction in the presence of [Fe(CN)6]
-3/-4, under a potential range 
of -0.3 to 1.5 V, and with a scan rate of 50 mV/s. 
2.7. Cyclic voltammetry analysis  
After osteopontin incubation, the electrochemical analyses were done as those performed after 
aptamers immobilization and the obtained current peak was recorded. The electrochemical 
analysis was performed at room temperature. The current decrease was calculated through 
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relative current change, ( ∆I %), the difference between the current values of the voltammogram 
oxidation peak recorded after analyzing the protein solution and that recorded after aptamer 
immobilization divided by this last one, using the equation:  
 
∆I %= (I0 - I1)/ I0 x 100 
 
where, ∆I is the relative current change; I0 and I1 represent the current measured using the 
information regarding the oxidation peaks before and after the sample treatment, respectively. 
 
The detection limit (LOD) and quantification limit (LOQ) were calculated based on the linear 
relationship obtained between different rhOPN concentrations and ∆I % values of the oxidation 
peak current. The detection limit is calculated by the equation LOD = 3.3(SD/b) and the 
quantification limit is calculated by the equation LOQ = 10(SD/b), where SD is the standard 
deviation of the intercept and b is the average slope of the regression line (Ermer and Miller, 
2005). Additionally, repeatability assays were studied in order to evaluate the closeness of the 
agreement between the results of osteopontin immobilization made the same day with the same 
protein concentration but with different SPGEs. Finally, the specificity of the DNA aptasensor 
to other proteins was also evaluated by means of the electrochemical signal generated from the 
interaction between the DNA aptamer and a solution of each protein (THR, LYS and BSA; 200 
nM), under similar experimental conditions.  
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3. Results and discussion 
3.1. DNA aptamer selection  
As mentioned, aptamers are short single-stranded oligonucleotides that are able to bind to 
specific target molecules with high affinity and specificity. Binding occurs due to their specific 
and complex three-dimensional shapes that are characterized by stems, loops, bulges, hairpins, 
pseudoknots, triplexes, or quadruplexes. The aptamer-target binding is the result of structure 
compatibility, stacking of aromatic rings, electrostatic and van der Waals interactions, hydrogen 
bonding, or a combination of these effects (de-los-Santos-Álvarez et al., 2008; Lönne et al., 
2014; Stoltenburg et al., 2007; Strehlitz et al., 2012). In this work, a DNA aptamer (C10K7) 
previously isolated by the research team (Meirinho, 2016; Meirinho et al., 2017) through the 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) methodology towards 
rhOPN was selected. Several sequences (aptamers) were isolated and their applicability was 
theoretically evaluated taking into account the sequence’ Gibbs energy (∆G values, being the 
lowest one the most desirable, since it would correspond to the highest stability), their 
homology and capability to form stable secondary structures considering the aptamer full-
sequence (70 nucleotides, nt) or the random region (30 nt).  
According to the previous research (Meirinho, 2016; Meirinho et al., 2017) 19 clones were 
isolated and sequenced. The sequences that exhibited the lowest ∆G values for the full sequence 
with conserved regions (70 nt) were C10K2, C10K7, C10K3, C10K5, C10K9, C10K15 and 
C10K18. Considering the random region (30 nt), the sequences with the lower ∆G values were 
C10K2, C10K7 and C10K15 and these were found to form a stable secondary structure 
(Meirinho, 2016; Meirinho et al., 2017). A former sequence (C10K2) was already studied 
showing a satisfactory performance regarding the detection and quantification of osteopontin 
(Meirinho, 2016; Meirinho et al., 2017). In this work, the DNA aptamer C10K7 (Figure 7) was 
selected because of its low ∆G value, homology and ability to form stable secondary structures 
considering the aptamer full-sequence (70 nucleotides, nt) or the random region (30 nt). 
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Figure 7. Secondary structure of the selected C10K7 DNA aptamer. The DNA aptamer 
sequence of C10K7 with 70 and 30 nucleotides were previously analyzed using the MFold 
software (Meirinho, 2016). 
 
3.2. Electrochemical evaluation of the electrode surface  
The voltammetry assays were conducted after each preparation step of the aptasensor in order 
to verify the electrochemical behavior of the electrode surface, being the first phases the 
cleaning steps followed by the immobilization steps. The CV is considered a convenient and 
valuable tool to monitor the modifications of the surface of the electrodes. It allows measuring 
the electron transfer between the solution species and the electrode surface that must occur by 
tunneling either through the barrier or through the defects in the barrier (Olowu et al., 2011). 
Figure 8 shows the cyclic voltammograms recorded after each preparation step, using a 5 mM 
solution of [Fe(CN)6]
3-/4- in PBS solution as the electrochemical probe. As it can be observed 
from the cyclic voltammograms shown in Figure 8.A, a quasi-reversible voltammetric profile 
was recorded with the screen-printed gold electrodes (SPGEs: DS-C223AT) before any 
treatment (i.e., bare Au electrode full line in Figure 8.A), with potential variation between 
cathodic and anodic peaks of 100 mV (∆Ep) and with similar cathodic and anodic peaks current 
intensities (~25 A). The current response decreased significantly after the cleaning steps (i.e., 
AFC dashed line in Figure 8.A), which included the use of different H2SO4 solutions. The 
observed decrease may be due to achieving a homogeneous electrode surface. After the 
formation of the DPA self-assembled monolayer on the electrode surface (i.e., DPA dot line in 
Figure 8.A), an expected decrease of the peaks’ current intensities was observed, as well as an 
increase of ∆Ep, which may be due to the electron transfer blocking. Afterward, the electrode 
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surface was activated with EDC-NHS that leads to the activation of the carboxyl groups and 
results into an increase of the peaks current intensities (Figure 8.B). The activated carboxylic 
groups on the electrode surface facilitate the binding of the streptavidin amine’s groups. 
Comparing with the previous step, the streptavidin layer in the electrode surface increased the 
∆Ep value and decreased once more the current peaks’ intensities. After exposing the working 
surface electrode to ETA, with the aim to block any remaining activated carboxyl groups, the 
cyclic voltammogram obtained showed a decrease in the ∆Ep and of the current peaks’ intensity 
as compared with the previous one, which may be due to some non-specific blocking of the 
remaining free carboxylic groups. 
After the immobilization of the DNA aptamer on electrode surface (C10K7), a typical cyclic 
voltammogram (Figure 8.C) was recorded showing lower current peaks intensities when 
compared to the previous steps. This decrease can be due to the negative charges of the aptamer 
backbone phosphate group and [Fe(CN)6]
3−/4− redox probe, the electrostatic repulsive 
interaction is able of blocking the electron transfer (Bang et al., 2005). This result clearly 
demonstrates the effective immobilization of the aptamer onto the working electrode surface. 
After rhOPN incubation, the difference between the cyclic voltammograms obtained after the 
aptasensor preparation and after its incubation with a standard rhOPN solution (50.05 nM) is 
significant (Figure 8.C, dashed and dot lines, respectively). Actually, for the rhOPN analysis, 
the cyclic voltammogram showed the highest potential variation between peaks and the lowest 
current peaks when compared to all the previous steps. The decrease of peak current intensities 
demonstrates the aptamer-rhOPN complex formation, by means of the specific recognition 
increased hindered electron transfer. This “signal-off” sensing mechanism in the current, also 
called negative readout signal, after aptamer-target interaction may be attributed to a change of 
the aptamer conformation. The abovementioned voltammetric changes were similar to those 
previously described in the literature during the cleaning and immobilization steps of other 
SPGEs for the detection of osteopontin with RNA and DNA aptamers (Merinho et al., 2015, 
2017; Meirinho, 2016). 
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Figure 8. Cyclic voltammograms of 5 mM [Fe(CN)6]
3-/4- probe in PBS buffer solution of pH 
7.4 at a scan rate of 100 mV/s for all aptasensor preparation steps: bare Au electrode, 
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3.3. Repeatability  
For each rhOPN concentration evaluated, two SPGEs (DS-C223AT) were used for 
immobilization and if the results obtained with the two chips were not similar a third SPGE was 
used to confirm the results. Figure 9 shows two voltammograms obtained after the incubation 
of a rhOPN solution with the concentration of 50.05 nM, with two different chips, being the 
assays carried out on the same day and under the same operating conditions. A coefficient of 
variation of 7% was calculated using the standard deviation and the mean ∆I (%) values showed 
the satisfactory repeatability of the method. Indeed, Figure 9 shows an almost perfect 
superposition of the two voltammograms, which have similar cathodic and anodic peaks current 
intensities and similar relative current change (11.7% and 12.9%). 
 
  
3.4. Electrochemical detection of human OPN  
The performance of the aptasensor was evaluated under specific experimental conditions, 
taking into account its response (∆I% values) against standard solutions that contain different 
concentrations of rhOPN. Each rhOPN determination was carried out using different SPGEs. 
The cyclic voltammograms of the redox probe [Fe(CN)6]
3−/4− solution showed an 
electrochemical response that is related to the modification of the aptamer surface and, in this 



















Chip 1 Chip 2
  
Figure 9. Intra-day repeatability assays: cyclic voltammograms after rhOPN 
immobilization (50.05nM) for two different SPGEs. 
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The CV assays showed a decrease in the anodic and cathodic current responses (Ipa and Ipc) as 
a consequence of the increase of the rhOPN concentration. In Figure 10 it is shown the response 
obtained (∆I% values) as a function of the rhOPN concentration for a dynamic concentration 
range of 1.5 to 201 nM. The results showed an increase of the ∆I% values with the increase of 
the rhOPN concentration, being two distinct linear zones identified, one for rhOPN 
concentration up to 12.5 nM and another for concentrations ranging from 12.5 and 201 nM. 
Thus, two calibration curves were established by linear regression (Figures 11 and 12): 
 
∆I (%) = 4.8(±0.1) + 0.28(±0.02) × [OPN, nM]) for 1.5 nM  [OPN]  12.5 nM 
∆I (%) = 6.8(±0.2) + 0.107(±0.002) × [OPN, nM]) for 12.5 nM  [OPN]  201 nM 
    
Figure 10. Electrochemical aptasensor sensitivity analysis of rhOPN using an aptamer-
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Figure 12. The linear relationship between the ∆I (%) and the rhOPN concentrations, in the 
range of 1.5 to 12.5 nM. 
 
The linear determination coefficients (R2) were of 0.9940 and 0.9984 for the lowest and highest 
concentration ranges, being calculated the LOD and LOQ values based on the regression line 
coefficients of the calibration curve shown in Figure 12. The calculated LOD and LOQ values 
were equal to 1.3 nM and 3.95 nM (i.e., 84.5 ng/mL and 256.75 ng/mL, assuming a molecular 
weight of 65 kDa), respectively. These LOD and LOQ values were improved compared to all 
the previous work using CV and equal to the result previously found with SWV (Table 5), 
















∆I (%) = 6.8(±0.2) + 0.107(±0.002) × [OPN, nM]















∆I (%) = 4.8(±0.1) + 0.28(±0.02) × [OPN, nM]
1.5 ≤ [OPN]  12.5 nM
LOD = 1.3 nM
LOQ = 4.0 nM
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with SWV and the DNA C10K7 aptamer may allow a diminishing of the reported LOD and 
LOQ values and so foresee a possible practical application of this electrochemical tool. 
  
Table 5. Comparison of the analytical characteristics of the actual proposed DNA aptasensor 
with the previously reported methods for rhOPN detection. 
 
Detection method Characteristics of 
the method 










































 1.3 4.0 This Work 
 
Taking into consideration the reported range of OPN concentrations found in plasma samples 
from patients with breast cancer (up to 290 ng/mL) with either metastatic or recurrent breast 
cancer (Bramwell et al., 2014) the proposed aptasensor could be applied in both OPN detection 
and quantification. Also, as mentioned previously, the future application of other voltammetry 
techniques, such as SWV and DPV, could increase the sensitivity of the proposed analysis. 
Actually, the SWV compared to CV is a technique that presents a broader dynamic range and 
lower limit of detection. Also, SWV enables a faster analysis added to less consumption of 
electroactive compounds, as a consequence it reduces the blocking problems of the electrode 
surface (Dogan-Topal et al., 2010). Eventually, the use of aptamers as bioreceptors instead of 
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antigen or antibody (immunological detection) makes this method less expensive and an 
interesting commercial alternative. Added to that, the use of aptamers presents some advantages 
like ease and a reduced cost of production.   
3.5 Specificity of the DNA aptasensor to other proteins  
The specificity of an aptamer towards its target molecule has a huge importance in the 
evaluation of the aptasensor performance and it can be evaluated by comparing the DNA 
aptamer binding capability with the specific protein (rhOPN in this case) and with non-specific 
proteins. Non-specific binding to the aptasensor cause high background signals which leads to 
the decrease of its performance. Three proteins (THR, BSA and LYS) were evaluated as 
possible interferents similar to previous studies (Meirinho et al., 2015, 2017; Meirinho, 2016). 
These proteins were chosen to take into account their isoelectric points and molecular weights, 
as well as their distinctive features that may affect the aptasensor performance (Meirinho, 
2016). Thrombin (THR) was used because the OPN has a conserved thrombin cleavage domain 
(RSK (arginine168-lysine170) adjacent to the RGD domain). It is also a secreted serine protease 
found in the human blood (Beausoleil et al., 2011; Gursoy et al., 2010). The bovine serum 
albumin (BSA) is inert and similar to the human serum albumin (HSA), which also is present 
in high concentrations in human serum samples (Gokulrangan et al., 2005). Finally, lysozyme 
(LYS) was used as a control protein since it possesses the lowest molecular weight and highest 
peak current intensity compared with all the other proteins studied, it is also known to non-
specifically bind to nucleic acids (Gokulrangan et al., 2005). The relative current response 
(∆I%) for the interferent proteins tested was found to be negligible as compared to the specific 
binding response obtained with rhOPN as shown in Figure 13. The mean relative current 
intensity response for THR, BSA, LYS and OPN was 7.16%, 16.65%, 16.21% and 28.7% 
respectively. The DNA C10K7 aptasensor showed a better selectivity for THR but a lower 
selectivity to BSA and LYS when compared to the results obtained with another DNA 
aptasensor previously reported (Meirinho et al., 2015). The results also showed that the DNA 
aptamer had a good sensitivity to rhOPN when compared with the proteins BSA, LYS and 
THR. However, their ∆I % values cannot be neglected especially for LYS and BSA. Finally, 
these results suggest that this aptasensor still could be used to detect rhOPN in biological 
samples such as plasma, blood or serum. 
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Figure 13. The relative current response (∆I %) to non-specific proteins (200 nM): THR-
thrombin, BSA – bovine serum albumin and LYS – lysozyme and for specific-protein rhOPN 
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4. Conclusion and perspectives 
 
The aim of this work was to assess the enhancement performance of a novel aptasensor for the 
detection and quantification of human OPN, in order to conceive the development of new 
strategies for the early detection and diagnosis of different types of cancer. 
Electrochemical aptasensor devices have been widely explored for the detection of various 
proteins disease biomarkers, mostly due to their interesting features including high sensitivity, 
low-cost and simple preparation, reusability and rapid response. In this thesis, a screen-printed 
gold electrode (SPGE) with a gold working electrode (1.6 mm of diameter), was used as it 
allows reducing the amount of reagents and solutions required and miniaturizing the biosensor 
device. Additionally, aptamers have been reported as suitable bioreceptors due to their easy 
chemical production, high thermal stability and possibility to be modified with chemical groups 
that are useful for the functionalization of the electrode surfaces.  
In this work, a new DNA aptamer (C10K7), previously isolated through SELEX methodology 
by the research team, was selected and used. The results obtained are satisfying as the 
aptasensor showed high sensitivity, specificity and repeatability towards the detection of 
rhOPN. The detection and quantification limits are lower than those reported in previous works 
using CV and equal to those reported using SWV as it is considered to be a more sensitive tool 
compared to CV. In conclusion, the development of electrochemical aptasensor using this 
aptamer can be a simple and efficient strategy for the detection of relevant biomarkers, for the 
diagnosis and therapy monitoring, as well as a promising alternative to directly analyze complex 
samples such as biological fluids like blood or plasma. 
Despite the interesting and relevant results herein obtained, additional work is still needed to 
improve this study, like the use of SWV, a more sensitive tool, instead of CV as it may lead to 
a better detection and quantification limit and the evaluation of the human OPN detection by 
this DNA aptasensor in biological fluids such as blood and plasma. 
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